ReviewPharmaceuticals (Basel, Switzerland)2015
Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria.
Review in Pharmaceuticals (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 99 citations in OpenAlex.
- Bacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Bacteriophage-mediated biofilm control: a novel targeted strategy for the management of dental caries.Frontiers in cellular and infection microbiology · 2026Review
- Phage (cocktail)-antibiotic synergism: a new frontier in addressingFrontiers in microbiology · 2025Article
- Coacervate Dense Phase Displaces Surface-EstablishedJournal of the American Chemical Society · 2024Article
- Tracking of Bacteriophage Predation onSensors (Basel, Switzerland) · 2024Article
- Bacteriophage-mediated approaches for biofilm control.Frontiers in cellular and infection microbiology · 2024Review
- Optimization of Phage-Antibiotic Combinations against Staphylococcus aureus Biofilms.Microbiology spectrum · 2023Article
- Bacteriophage Adsorption: Likelihood of Virion Encounter with Bacteria and Other Factors Affecting Rates.Antibiotics (Basel, Switzerland) · 2023Review
- Salphage: Salvage bacteriophage therapy for a chronicIDCases · 2023Article
- Effective phage cocktail to combat the rising incidence of extensively drug-resistantEmerging microbes & infections · 2022Article
- Salphage: salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection - a case report.Acta orthopaedica · 2022Article
- E. coli biofilm formation and its susceptibility towards T4 bacteriophages studied in a continuously operating mixing - tubular bioreactor system.Microbial biotechnology · 2022Article
- Deconstructing the Phage-Bacterial Biofilm Interaction as a Basis to Establish New Antibiofilm Strategies.Viruses · 2022Review
- Article
- Review
- Bacteriophages as an Alternative Method for Control of Zoonotic and Foodborne Pathogens.Viruses · 2021Review
- Biological characteristics and anti-biofilm activity of a lytic phage against vancomycin-resistantIranian journal of microbiology · 2021Article
- Improving Phage-Biofilm In Vitro Experimentation.Viruses · 2021Article
- Novel therapeutic interventions towards improved management of septic arthritis.BMC musculoskeletal disorders · 2021Review
- Potential Use of Adjuvant Bacteriophage Therapy With Debridement, Antibiotics, and Implant Retention Surgery to Treat Chronic Prosthetic Joint Infections.Open forum infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages are the viruses of bacteria. In the guise of phage therapy they have been used for decades to successfully treat what are probable biofilm-containing chronic bacterial infections. More recently, phage treatment or biocontrol of biofilm bacteria has been brought back to the laboratory for more rigorous assessment as well as towards the use of phages to combat environmental biofilms, ones other than those directly associated with bacterial infections. Considered in a companion article is the inherent ecological utility of bacteriophages versus antibiotics as anti-biofilm agents. Discussed here is a model for phage ecological interaction with bacteria as they may occur across biofilm-containing ecosystems. Specifically, to the extent that individual bacterial types are not highly abundant within biofilm-containing environments, then phage exploitation of those bacteria may represent a "Feast-or-famine" existence in which infection of highly localized concentrations of phage-sensitive bacteria alternate with treacherous searches by the resulting phage progeny virions for new concentrations of phage-sensitive bacteria to infect. An updated synopsis of the literature concerning laboratory testing of phage use to combat bacterial biofilms is then provided along with tips on how "Ecologically" such phage-mediated biofilm control can be modified to more reliably achieve anti-biofilm efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.